Patent US4378356A successfully refreshed from Google Patents.
US4378356A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Multi-phase combination-type sequential preparation for oral contraception and method of oral contraception
Assignee: Akzo NV
•
Filing: 1981-03-16
•
Granted: 1983-03-29
•
Expires: 2001-03-16
Abstract
Abstract The invention relates to a multiphase combination-type sequential preparation for oral contraception consisting of 20-22 tablets each containing a gestagen and an oestrogen wherein a first phase consists of 5-8 tablets, each of which contains a low dose of gestagen and a relatively high dose of oestrogen, a second phase of 5-8 tablets each having a gestagen dose which is greater than that during the first phase and an oestrogen dose which is smaller than that in the first phase, and a third phase of 5-11 tablets each of which has a gestagen dose equal to or greater than that during the second phase and an oestrogen dose equal to or less than that in the second phase, and to a method of oral contraception using said preparation.
Inventors
- 👤 Evert De Jager
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 13:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/565; A61H; A61H33/00; A61H33/60; A61H33/601; A61H33/6021; A61H33/6052; A61H33/6063; A61K31/57; B; B05; B05B; B05B3/00; B05B3/02; B05B3/04; B05B3/0417; B05B3/0423; A61H2201/00; A61H2201/12; A61H2201/1238; A61H33/02
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
182 words
A multi-phase combination-type sequential preparation for oral contraception consisting of 20-22 tablets each containing a gestagen and an oestrogen characterized in that a first phase consists of 5-8 tablets, each of which contains a low dose of gestagen and a relatively high dose of oestrogen, a second phase of 5-8 tablets each having a gestagen dose which is greater than that during the first phase and an oestrogen dose which is smaller than that in the first phase, and a third phase of 5-11 tablets each of which has a gestagen dose equal to or greater than that during the second phase and an oestrogen dose equal to or less than that in the second phase, wherein the gestagen is selected from the group consisting of desogestrel and the 3-oxo derivative thereof, and the oestrogen is ethinyloestradiol, the amount of gestagen in the first phase tablet being less than or equal to 0.050 mg, the amount of oestrogen in said first phase tablet being less than 0.050 mg, the amount of gestagen in the three phases being in the ratio of 1:1.5-5:3-6.
Claim 2
Dependent Claim
182 words
A multi-phase combination-type sequential preparation for oral contraception consisting of 20-22 tablets each containing a gestagen and an oestrogen characterized in that a first phase consists of 5-8 tablets, each of which contains a low dose of gestagen and a relatively high dose of oestrogen, a second phase of 5-8 tablets each having a gestagen dose which is greater than that during the first phase and an oestrogen dose which is smaller than that in the first phase, and a third phase of 5-11 tablets each of which has a gestagen dose equal to or greater than that during the second phase and an oestrogen dose equal to or less than that in the second phase, wherein the gestagen is selected from the group consisting of desogestrel and the 3-oxo derivative thereof, and the oestrogen is ethinyloestradiol, the amount of gestagen in the first phase tablet being less than or equal to 0.050 mg, the amount of oestrogen in said first phase tablet being less than 0.050 mg, the amount of gestagen in the three phases being in the ratio of 1:1.5-5:3-6.
Claim 3
Dependent Claim
44 words
Preparation according to claim 1, characterized in that the amount of oestrogen per tablet expressed in mg ethinyloestradiol in the first phase is between 0.030 and 0.045, in the second phase between 0.020 and 0.035 and in the third phase between 0.015 and 0.030.
Claim 4
Dependent Claim
25 words
Preparation as in claim 2, characterized in that the total amount of oestrogen in the 20-22 tablets expressed in mg ethinyloestradiol is less than 0.750.
Claim 5
Dependent Claim
39 words
Preparation as in claim 1, characterized in that the total amount of gestagen in the 20-22 tablets expressed in mg desogestrel is between 2 and 4 times as great as the total amount of oestrogen expressed in mg ethinyloestradiol.
Claim 6
Dependent Claim
72 words
Preparation as in claim 1, characterized in that the first phase consists of 7 tablets each of which contains, as the gestagen, 0.025 mg desogestrel and, as the oestrogen, 0.040 mg ethinyloestradiol, the second phase consists of 7 tablets each containing 0.125 mg desogestrel and 0.030 mg ethinyloestradiol, and the third phase consists of 7 tablets each of which contains the same amount of gestagen and oestrogen as in the second phase.
Claim 7
Dependent Claim
74 words
Preparation as in claim 1, characterized in that the first phase consists of 7 tablets each of which contains, as the gestagen, 0.025 mg desogestrel and, as the oestrogen, 0.040 mg ethinyloestradiol, the second phase consists of 7 tablets each of which contains 0.125 mg desogestrel and 0.025 mg ethinyloestradiol, and the third phase consists of 7 tablets each of which contains the same amount of gestagen and oestrogen as in the second phase.
Claim 8
Dependent Claim
69 words
Preparation as in claim 1, characterized in that the first phase consists of 7 tablets each of which contains, as the gestagen, 0.050 mg desogestrel and, as the oestrogen, 0.040 mg ethinyloestradiol, the second phase consists of 7 tablets each of which contains 0.100 mg desogestrel and 0.030 mg ethinyloestradiol, and the third phase consists of 7 tablets each of which contains 0.200 mg desogestrel and 0.020 mg ethinyloestradiol.
Claim 9
Dependent Claim
69 words
Preparation as in claim 1, characterized in that the first phase consists of 7 tablets each of which contains, as the gestagen, 0.025 mg desogestrel and, as the oestrogen, 0.040 mg ethinyloestradiol, the second phase consists of 7 tablets each of which contains 0.075 mg desogestrel and 0.030 mg ethinyloestradiol, and the third phase consists of 7 tablets each of which contains 0.125 mg desogestrel and 0.025 mg ethinyloestradiol.
Claim 10
Independent Claim
55 words
A method of oral contraception which comprises orally administering the tablets of the combination-type preparation as defined in any one of claims 2, 3, 4, 5, 6, 7, 8 or 1 to a fertile female for 20-22 days, said tablets being administered according to the prescribed sequence of phases while administering one tablet a day.
Claim 11
Dependent Claim
17 words
Preparation according to claim 3, wherein the amount of oestrogen is less than 0.700 mg of ethinyloestradiol.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-03-28 | 1986-09-27 | 1987-03-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-03-28 | 1990-09-27 | 1991-03-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-03-28 | 1994-09-27 | 1995-03-29 | $7700.00 | Window Closed / Lapsed |